Hepatitis C virus (HCV) is a hepatotropic RNA virus that causes progressive liver damage,
which might result in liver cirrhosis and hepatocellular carcinoma. Globally, between 64 and …

Sofosbuvir (SOVALDI®), a potent, once-daily, orally administered nucleotide analog prodrug
inhibitor of the hepatitis C virus (HCV) NS5B polymerase is approved in the USA, EU …

Background & Aims Hepatitis C virus (HCV) infection is an independent risk factor for
chronic kidney disease and leads to faster liver disease progression in patients requiring …

Methods Of the 15 patients, 12 (80%) were on dialysis (11 hemodialysis, one peritoneal)
and the rest had a GFR between eight and 15 ml/min. The University of Miami IRB approved …

Hepatitis C virus (HCV) infection is more prevalent and is associated with higher mortality in
patients receiving dialysis and in kidney transplant recipients than in the general population …

It has been estimated by the World Health Organization (WHO) that over 71 million people
were infected with the hepatitis C virus (HCV) in 2015. Since then, a number of highly …

The development and publication of this guideline were supported by KDIGO. The opinions
or views expressed in this professional education supplement are those of the authors and …

Several direct‐acting antiviral agents (DAAs) have marketing authorization in Europe and in
the USA and have changed the landscape of hepatitis C treatment: each DAA has its own …

DAA‐based regimens for chronic hepatitis C infection encourage treatment of “difficult‐to‐
treat” cohorts. This study investigated efficacy and safety of DAA‐based regimens in HCV …

Hepatitis C virus (HCV)-infected patients often suffer from liver cirrhosis, which can be
complicated by renal impairment. Therefore, in this review we describe the treatment …